---
symbol: "RHOH"
type: "gene"
col: 9649
ensembl_id: "ENSG00000168421"
name: "ras homolog family member H"
location: "4p14"
module: 19
arm: "+"
pooled_cpm: 6.19
n_lines_expressing: 28
n_dd_up: 11
n_dd_down: 10
n_dd_up_clean: 5
n_dd_down_clean: 10
in_vector_space: true
direction_upstream: 2
direction_downstream: 0
tags: ["gene", "module/019"]
generated_by: "tahoemap"
---

# RHOH

*ras homolog family member H* — 4p14

## At a glance

> [!summary] In this data
> Pooled over the cell lines (median), raised significantly by 11 drug-doses (6 with an alert ⚠); the strongest is [[Dinaciclib (drug)]] 0.5 µM: 11.1× (z +21.3, q 0e+00, up in 6 of 11 measured lines) ⚠ toxic; transcription drop. The strongest without an alert is [[Idarubicin (hydrochloride) (drug)]] 5 µM: 2.53× (z +10.9, q 1e-25, up in 9 of 19 measured lines).
> Pooled over the cell lines (median), lowered significantly by 10 drug-doses (none with an alert); the strongest is [[Belinostat (drug)]] 5 µM: 0.605× (z -4.5, q 0.005, down in 10 of 22 measured lines).
> Its strongest partners by |cos| (100 of its 100 nearest are replicated: the same sign with fdr ≤ 0.10 in two random halves of the compounds; 1 carry an alert, ⚠ + the reason: not replicated, same locus, or the partner in the vector space only through flagged drug-doses): it moves with [[SERPINB11]] (+0.77, fdr 7e-06), [[DPP10]] (+0.73, fdr 7e-06), [[LINC01257]] (+0.72, fdr 1e-05).
> It is in [[Module 019]], a single-armed module (Neuronal System).
> Probable direction (from the cell lines, not proof of direct regulation): 2 arrows point to it, the strongest [[MAP2K1]] → it (grade B ⚠); none goes from it. See Direction (probable) below.

## Drugs that raise it

*Pooled over the cell lines (median). Every drug-dose with |z| ≥ 3 or q < 0.10, strongest first: 11 in all, 6 with an alert ⚠. 11 of them raise it significantly (**bold**: q < 0.10, ≥ 1.2×), 6 with an alert ⚠. ⚠ = an artifact flag on the drug-dose or on this gene: the change may come from cell death, a drop in transcription, a shift in the cell-cycle mix, a plate that does not reproduce or a well-position problem rather than from regulation of this gene; it is shown, not left out. `tables/drug_effects.parquet` col == 9649.*

| Drug-dose | Alert | Fold | z | q | Lines up / measured | Dose pattern | Caveats |
|---|---|---|---|---|---|---|---|
| [[Dinaciclib (drug)]] 0.5 µM | ⚠ toxic; transcription drop | **11.1×** | +21.3 | 0e+00 | 6/11 (NCI-H2030, SW 900, …) | all doses, stronger at high dose | cell-cycle shift (explains ~0% here); composition shift |
| [[Dinaciclib (drug)]] 5 µM | ⚠ toxic; transcription drop | **11.5×** | +20.7 | 0e+00 | 0/4 | all doses, stronger at high dose | cell-cycle shift (explains ~0% here); composition shift |
| [[Dinaciclib (drug)]] 0.05 µM | ⚠ toxic; transcription drop | **7.56×** | +13.8 | 5e-41 | 4/7 (NCI-H1573, PANC-1, …) | all doses, stronger at high dose | cell-cycle shift (explains ~0% here); composition shift; noisy plate (z scaled) |
| [[Idarubicin (hydrochloride) (drug)]] 5 µM |  | **2.53×** | +10.9 | 1e-25 | 9/19 (HEC-1-A, LoVo, …) | rises with dose | cell-cycle shift (explains ~1% here) |
| [[Auranofin (drug)]] 5 µM |  | **1.65×** | +4.4 | 0.001 | 6/20 (HOP62, LoVo, …) | rises with dose |  |
| [[Docetaxel (drug)]] 0.05 µM | ⚠ transcription drop | **1.67×** | +4.3 | 0.002 | 1/13 (PANC-1) | inconsistent across doses | low cells (technical?); cell-cycle shift (explains ~0% here); position effect removed |
| [[TAK-901 (drug)]] 0.05 µM |  | **1.61×** | +4.0 | 0.006 | 3/20 (PANC-1, A549, …) | inconsistent across doses |  |
| [[Doxorubicin (hydrochloride) (drug)]] 5 µM |  | **1.58×** | +3.9 | 0.008 | 2/16 (HOP62, HEC-1-A) | top dose only | cell-cycle shift (explains ~2% here) |
| [[Filgotinib (drug)]] 5 µM |  | **1.52×** | +3.7 | 0.016 | 8/25 (NCI-H1573, NCI-H460, …) | rises with dose |  |
| [[Niclosamide (olamine) (drug)]] 5 µM | ⚠ toxic | **1.51×** | +3.5 | 0.026 | 2/14 (SW 900, HEC-1-A) | top dose only | cell-cycle shift (explains ~0% here) |
| [[Topotecan (hydrochloride) (drug)]] 5 µM | ⚠ toxic | **1.51×** | +3.5 | 0.026 | 3/12 (PANC-1, SW 900, …) | rises with dose | cell-cycle shift (explains ~11% here) |

## Drugs that lower it

*Pooled over the cell lines (median). Every drug-dose with |z| ≥ 3 or q < 0.10, strongest first: 10 in all, none with an alert. 10 of them lower it significantly (**bold**: q < 0.10, ≥ 1.2×), none with an alert. ⚠ as above. `tables/drug_effects.parquet` col == 9649.*

| Drug-dose | Alert | Fold | z | q | Lines down / measured | Dose pattern | Caveats |
|---|---|---|---|---|---|---|---|
| [[Belinostat (drug)]] 5 µM |  | **0.605×** | -4.5 | 0.005 | 10/22 (NCI-H460, NCI-H661, …) | rises with dose | cell-cycle shift (explains ~0% here) |
| [[Brivudine (drug)]] 5 µM |  | **0.414×** | -4.1 | 0.012 | 6/21 (NCI-H460, COLO 205, …) | top dose only | plate-row cell shift; noisy plate (z scaled) |
| [[Ouabain (Octahydrate) (drug)]] 0.5 µM |  | **0.653×** | -3.8 | 0.028 | 6/20 (NCI-H460, BT-474, …) | rises with dose | cell-cycle shift (explains ~12% here) |
| [[Cobimetinib (drug)]] 5 µM |  | **0.647×** | -3.7 | 0.028 | 5/17 (LOX-IMVI, COLO 205, …) | top dose only |  |
| [[Ouabain (Octahydrate) (drug)]] 5 µM |  | **0.670×** | -3.6 | 0.043 | 10/24 (NCI-H460, NCI-H1792, …) | rises with dose | cell-cycle shift (explains ~20% here); composition shift |
| [[Trametinib (DMSO_TF solvate) (drug)]] 0.05 µM |  | **0.619×** | -3.3 | 0.086 | 1/22 (hTERT-HPNE) | inconsistent across doses | noisy plate (z scaled) |
| [[Binimetinib (drug)]] 0.5 µM |  | **0.729×** | -3.3 | 0.086 | 5/22 (SHP-77, COLO 205, …) | inconsistent across doses | noisy plate (z scaled) |
| [[Bisoprolol (hemifumarate) (drug)]] 0.5 µM |  | **0.701×** | -3.2 | 0.098 | 2/21 (LOX-IMVI, NCI-H2030) | inconsistent across doses |  |
| [[Tirabrutinib (drug)]] 5 µM |  | **0.692×** | -3.2 | 0.098 | 4/22 (LOX-IMVI, hTERT-HPNE, …) | inconsistent across doses |  |
| [[Rutin (trihydrate) (drug)]] 0.05 µM |  | **0.634×** | -3.1 | 0.098 | 1/22 (HOP62) | inconsistent across doses | noisy plate (z scaled) |

*`cell-cycle shift`: the drug-dose moved its cells into or out of S or G2/M. Its alert says how much of this gene's change that shift would explain (`cc_share`), from the gene's own slopes on the S-phase and G2/M modules (`tables/genes.parquet`: +0.05 per unit of S-phase module lfc, -0.21 per unit of G2/M module lfc). Fitted slopes are attenuated by noise, so the rule multiplies them by 2: a row keeps the alert when the shift would then explain 50% of the change or more, or leave less than a 1.2× change unexplained (an alert's ~N% is the share at the fitted slopes). `cell-cycle shift (explains ~N% here)` = the shift explains only about N% of this change, and even with the slopes multiplied by 2 less than 50%, so for this gene it is no artifact and carries no alert.*

## In which cell lines

*`tables/line_effects.parquet` col == 9649. CPM = the line's own level (n.m. = not measured: the line does not express it, or below 0.25 × its pooled level, where its reads are mostly ambient RNA; no per-line values). Up / down = drug-doses moving it ≥ 1.5× at per-line |z| ≥ 8.4 (calibrated on this run, `tables/info.json`; about 0.0492 such calls per gene and line are expected by chance over the 1,026 clean drug-doses), all of them; in brackets how many of those carry an alert (⚠: an artifact flag on the drug-dose or on this gene). The strongest of them is shown, with its alert, and after it the strongest without an alert when that is another one. Most responsive lines first.*

| Line | TP53 | CPM | Up | Down | Strongest up | Strongest down |
|---|---|---|---|---|---|---|
| [[NCI-H460 (line)]] | wt | 69.7 | 0 | 17 (11 ⚠) | — | [[Homoharringtonine (drug)]] 5 µM 0.0307× (z -23.5) ⚠ cell-cycle shift, explains ~0% of this change · without an alert: [[Ouabain (Octahydrate) (drug)]] 5 µM 0.0283× (z -17.9) |
| [[NCI-H661 (line)]] | alt | 168 | 0 | 4 (1 ⚠) | — | [[Panobinostat (drug)]] 5 µM 0.0597× (z -12.2) |
| [[BT-474 (line)]] | alt | 14.2 | 0 | 3 (2 ⚠) | — | [[Digitoxin (drug)]] 0.5 µM 0.0331× (z -12.7) ⚠ cell-cycle shift, explains ~36% of this change · without an alert: [[Ouabain (Octahydrate) (drug)]] 0.5 µM 0.0391× (z -12.1) |
| [[COLO 205 (line)]] | alt | 24.5 | 0 | 2 (1 ⚠) | — | [[Panobinostat (drug)]] 0.5 µM 0.0204× (z -17.5) ⚠ cell-cycle shift, explains ~20% of this change · without an alert: [[Panobinostat (drug)]] 5 µM 0.108× (z -10.0) |
| [[NCI-H1573 (line)]] | alt | 7.25 | 0 | 1 (1 ⚠) | — | [[Digitoxin (drug)]] 0.05 µM 0.0505× (z -10.7) ⚠ cell-cycle shift, explains ~27% of this change |
| [[SW 900 (line)]] | alt | 7.58 | 0 | 1 (1 ⚠) | — | [[Homoharringtonine (drug)]] 5 µM 0.0775× (z -10.3) ⚠ cell-cycle shift, explains ~0% of this change |
| [[A-172 (line)]] | wt | 0.767 n.m. | — | — | — | — |
| [[A-427 (line)]] | wt | 1.53 n.m. | — | — | — | — |
| [[A498 (line)]] | wt | 0.995 n.m. | — | — | — | — |
| [[A549 (line)]] | wt | 1.64 | 0 | 0 | — | — |
| [[AN3 CA (line)]] | alt | 1.99 | 0 | 0 | — | — |
| [[AsPC-1 (line)]] | alt | 1.48 n.m. | — | — | — | — |
| [[C-33 A (line)]] | alt | 1.90 | 0 | 0 | — | — |
| [[C32 (line)]] | wt | 1.28 n.m. | — | — | — | — |
| [[CFPAC-1 (line)]] | alt | 2.36 | 0 | 0 | — | — |
| [[CHP-212 (line)]] | wt | 1.66 | 0 | 0 | — | — |
| [[H4 (line)]] | wt | 2.53 | 0 | 0 | — | — |
| [[HCT15 (line)]] | alt | 1.26 n.m. | — | — | — | — |
| [[HEC-1-A (line)]] | alt | 2.01 | 0 | 0 | — | — |
| [[HepG2_C3A (line)]] | wt | 3.21 | 0 | 0 | — | — |
| [[HOP62 (line)]] | alt | 1.78 | 0 | 0 | — | — |
| [[Hs 766T (line)]] | wt | 0.952 n.m. | — | — | — | — |
| [[HS-578T (line)]] | alt | 1.16 n.m. | — | — | — | — |
| [[HT-29 (line)]] | alt | 1.19 n.m. | — | — | — | — |
| [[hTERT-HPNE (line)]] | wt | 1.86 | 0 | 0 | — | — |
| [[J82 (line)]] | alt | 0.988 n.m. | — | — | — | — |
| [[KATO III (line)]] | alt | 1.13 n.m. | — | — | — | — |
| [[LoVo (line)]] | wt | 1.71 | 0 | 0 | — | — |
| [[LOX-IMVI (line)]] | wt | 2.18 | 0 | 0 | — | — |
| [[LS 180 (line)]] | wt | 0.916 n.m. | — | — | — | — |
| [[MIA PaCa-2 (line)]] | alt | 0.645 n.m. | — | — | — | — |
| [[NCI-H1792 (line)]] | alt | 11.6 | 0 | 0 | — | — |
| [[NCI-H2030 (line)]] | alt | 3.97 | 0 | 0 | — | — |
| [[NCI-H2122 (line)]] | alt | 5.43 | 0 | 0 | — | — |
| [[NCI-H23 (line)]] | alt | 2.95 | 0 | 0 | — | — |
| [[NCI-H2347 (line)]] | alt | 1.14 n.m. | — | — | — | — |
| [[NCI-H596 (line)]] | alt | 8.19 | 0 | 0 | — | — |
| [[Panc 03.27 (line)]] | alt | 0.708 n.m. | — | — | — | — |
| [[PANC-1 (line)]] | alt | 1.59 | 0 | 0 | — | — |
| [[RKO (line)]] | wt | 1.23 n.m. | — | — | — | — |
| [[RPMI-7951 (line)]] | alt | 1.18 n.m. | — | — | — | — |
| [[SHP-77 (line)]] | alt | 4.47 | 0 | 0 | — | — |
| [[SK-MEL-2 (line)]] | alt | 0.844 n.m. | — | — | — | — |
| [[SNU-1 (line)]] | wt | 1.96 | 0 | 0 | — | — |
| [[SNU-423 (line)]] | alt | 0.926 n.m. | — | — | — | — |
| [[SW 1088 (line)]] | alt | 2.09 | 0 | 0 | — | — |
| [[SW 1271 (line)]] | alt | 2.59 | 0 | 0 | — | — |
| [[SW1417 (line)]] | alt | 1.24 n.m. | — | — | — | — |
| [[SW48 (line)]] | wt | 1.31 n.m. | — | — | — | — |
| [[SW480 (line)]] | alt | 0.861 n.m. | — | — | — | — |

## Genes that move with it

*Strongest of its 100 nearest partners by |cos| (`relations/gene_relations.parquet` col_a == 9649), and any of the 12 strongest without an alert below them; halves = cos in the spaces fitted on two random halves of the compounds (a hash split of the compound names). Evidence: `both halves` = replicated: the same sign in both, |cos| ≥ 0.2 in each and fdr ≤ 0.10; ⚠ `one half` = strong in one of the two random halves only — not replicated, no error estimate; ⚠ `not reproduced` = neither. Other alerts: ⚠ same locus / read-through risk (neighbours on the genome can correlate for that reason alone), and `GENE ⚠` = the partner is in the vector space only through flagged drug-doses (all its evidence carries an artifact flag for it). A partner with an alert is shown in its place, not left out. A correlation across drugs and lines, not evidence that one gene regulates the other.*

*100 of its nearest partners move with it, 1 of them with an alert (⚠; 0 not replicated); shown: the 12 strongest.*

| Gene | cos | Halves | Evidence | fdr | Notes |
|---|---|---|---|---|---|
| [[SERPINB11]] | +0.77 | +0.73 / +0.77 | both halves | 7e-06 | **novel candidate** |
| [[DPP10]] | +0.73 | +0.70 / +0.69 | both halves | 7e-06 |  |
| [[LINC01257]] | +0.72 | +0.56 / +0.72 | both halves | 1e-05 | **novel candidate** |
| [[LAMB4]] | +0.68 | +0.54 / +0.60 | both halves | 1e-05 | **novel candidate** |
| [[KCNK2]] | +0.68 | +0.60 / +0.67 | both halves | 7e-06 |  |
| [[ADGRD1]] | +0.68 | +0.60 / +0.71 | both halves | 7e-06 |  |
| [[PAX7]] | +0.68 | +0.60 / +0.63 | both halves | 7e-06 |  |
| [[LINC01035]] | +0.67 | +0.61 / +0.70 | both halves | 7e-06 |  |
| [[RTN1]] | +0.67 | +0.60 / +0.63 | both halves | 7e-06 |  |
| [[SPDYE10]] | +0.67 | +0.57 / +0.67 | both halves | 9e-06 |  |
| [[GREM2]] | +0.66 | +0.58 / +0.70 | both halves | 7e-06 |  |
| [[GLP2R]] | +0.66 | +0.56 / +0.63 | both halves | 1e-05 |  |

## Genes that move opposite

None among its nearest partners: everything close to it moves the same way.

## Direction (probable)

*Arrows SOURCE → TARGET of the direction stage (`direction/edges.parquet`), each from a test (q < 0.10 in its family of tests: over the whole table, or for a lead - grade C - within its own group) of a recorded mutation, a natural knockout (lines that do not express a gene), compounds that target a gene, or a gene's natural level. A probable direction, from the screen's cell lines: not proof of direct regulation. Grades: A strong, B read its alerts, C a glimpse; ⚠ = a reason for doubt, shown in place. How to read them, and this run's controls: [[Probable direction]].*

### Upstream of this gene

*2 arrows, 2 of them with an alert ⚠; grade A 0, B 2, C 0.*

| Source | Grade | Direction (probable) | Evidence | Effect | q | Alerts |
|---|---|---|---|---|---|---|
| [[MAP2K1]] | B | MAP2K1 activity raises RHOH's level | compounds that target MAP2K1: 3 of 4 lower it (Binimetinib, Cobimetinib, Trametinib) | 75% of the class's compounds vs 2.5% of all compounds | 0.044 | ⚠ off-target possible; 3 compounds |
| [[CHL1]] | B | CHL1 activity raises RHOH's level | lines that do not express CHL1 (42) vs lines expressing it (8) | 2.74× lower at baseline in the lines without CHL1 | 0.086 | ⚠ within organs, on part of the lines; co-occurs with TP53, KRAS; also absent: LHFPL3-AS1, GSG1L2, ENSG00000241168 |

### Downstream of this gene

None: no arrow goes from this gene (to a gene, or to the cells under a drug-dose).

## Where it sits

- **Module**: [[Module 019]] — Neuronal System; 196 genes; every member is in the + arm (projection on the module's main direction 0.725). A single-armed module: the two sides of its main direction do not form two opposite arms (mean cos between them -0.17; a − arm needs ≥ 5 genes on its side and a mean cos ≤ -0.2), so all its genes count as +.
- **Nodal map** (x, y) = (45.8, 36.6); signed map (43.2, 44.8). **Vector** length 49.8, 10.7% of its response variance represented; |z| ≥ 3 in 530 contexts (`embed/genes.parquet`).

**Predicted by the vector space**: the drug-doses whose vectors predict the largest rise and fall (gene vector · drug-dose vector, in z units), next to the observed z (`atlas/effects/DD_z.npy`): the 5 strongest predictions over all drug-doses and the 5 strongest of those without an artifact flag, together. ⚠ = an artifact flag on the drug-dose (or on this gene, where `tables/drug_effects.parquet` has the pair): its observed z may come from what the drug-dose did to the cells.

|  | Drug-dose | Alert | Predicted z | Observed z |
|---|---|---|---|---|
| rise | [[Dinaciclib (drug)]] 5 µM | ⚠ toxic; transcription drop | +6.0 | +20.7 |
|  | [[Dinaciclib (drug)]] 0.5 µM | ⚠ toxic; transcription drop | +5.6 | +21.3 |
|  | [[Dinaciclib (drug)]] 0.05 µM | ⚠ toxic; transcription drop | +5.1 | +13.8 |
|  | [[Idarubicin (hydrochloride) (drug)]] 5 µM |  | +4.6 | +10.9 |
|  | [[Auranofin (drug)]] 5 µM |  | +3.1 | +4.4 |
|  | [[Mitoxantrone (dihydrochloride) (drug)]] 5 µM |  | +2.2 | +1.9 |
|  | [[TAK-901 (drug)]] 0.05 µM |  | +1.6 | +4.0 |
|  | [[Tucidinostat (drug)]] 5 µM |  | +1.5 | +0.6 |
|  | [[Docetaxel (Trihydrate) (drug)]] 0.5 µM |  | +1.5 | +2.2 |
| fall | [[Trametinib (DMSO_TF solvate) (drug)]] 0.05 µM |  | -1.8 | -3.3 |
|  | [[Trametinib (drug)]] 5 µM | ⚠ cell-cycle shift | -1.7 | -2.0 |
|  | [[Radotinib (drug)]] 5 µM |  | -1.4 | -2.8 |
|  | [[Lucanthone (drug)]] 0.05 µM |  | -1.3 | -2.6 |
|  | [[Neratinib (maleate) (drug)]] 5 µM |  | -1.3 | -2.0 |
|  | [[Artesunate (drug)]] 0.5 µM |  | -1.2 | -2.2 |

## What is on record

|  |  |
|---|---|
| Name | ras homolog family member H |
| Locus type | gene with protein product (protein-coding gene) |
| Location | 4p14 — chr4:40,191,011-40,246,967 (+) |
| Ensembl biotype | protein_coding |
| Also known as | TTF; previously ARHH |
| Gene groups (HGNC) | Rho family GTPases |
| Hallmark sets | IL2_STAT5_SIGNALING |
| Reactome | 4 pathways, smallest: RHOH GTPase cycle; RHO GTPase cycle; Signaling by Rho GTPases |
| Matched by | ensembl_id |

**Function**, from UniProt [Q15669](https://www.uniprot.org/uniprotkb/Q15669) (Rho-related GTP-binding protein RhoH):

> Negative regulator of hematopoietic progenitor cell proliferation, survival and migration. Critical regulator of thymocyte development and T-cell antigen receptor (TCR) signaling by mediating recruitment and activation of ZAP70. Required for phosphorylation of CD3Z, membrane translocation of ZAP70 and subsequent activation of the ZAP70-mediated pathways. Essential for efficient beta-selection and positive selection by promoting the ZAP70-dependent phosphorylation of the LAT signalosome during …

**Summary**, from NCBI Gene [399](https://www.ncbi.nlm.nih.gov/gene/399):

> The protein encoded by this gene is a member of the Ras superfamily of guanosine triphosphate (GTP)-metabolizing enzymes. The encoded protein is expressed in hematopoietic cells, where it functions as a negative regulator of cell growth and survival. This gene may be hypermutated or misexpressed in leukemias and lymphomas. Chromosomal translocations in non-Hodgkin's lymphoma occur between this locus and B-cell CLL/lymphoma 6 (BCL6) on chromosome 3, leading to the production of fusion …

**Accessions** — [HGNC:686](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:686) · Entrez [399](https://www.ncbi.nlm.nih.gov/gene/399) · UniProt [Q15669](https://www.uniprot.org/uniprotkb/Q15669) · Ensembl [ENSG00000168421](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000168421)

## Data

Gene col 9649: `tables/genes.parquet`, `tables/line_effects.parquet` (50 rows) and `tables/drug_line_top.parquet` (col == 9649); `tables/drug_effects.parquet` (21 rows, flagged included); `relations/gene_relations.parquet` (col_a == 9649, 100 rows); `atlas/effects/DD_lfc|DD_z|DD_qup|DD_qdn.npy` [:, 9649]; `tensor/DDL_lfc|DDL_z.npy` [9649]; `embed/gene_vectors.npy` [9649]; `graph/nodes.parquet`; `direction/edges.parquet` (source_col == 9649 or target_col == 9649). Every well: [[RHOH — plates]].

## Sources

Generated by `tahoemap vault` (v4) from the tables of the run; do not edit this note, it is rebuilt on every run. No written note yet: write `tahoemap/vault_seed/genes/RHOH.md` and rerun `tahoe vault`.
Registry text: `reference/annotations.parquet` (HGNC, Ensembl GRCh38, UniProt, NCBI Gene; download dates in `reference/sources.json`). Paths are relative to the run folder.
